When Your Body’s Immune System Attacks Your Blood: FDA Approves First Treatment for Warm Autoimmune Hemolytic Anemia

A Rare Disease Gets Its First FDA-Approved Medicine—And It Works Differently Than Anything Available Before Imagine your immune system getting the signals completely wrong. Instead of protecting you from infection,…

Continue Reading When Your Body’s Immune System Attacks Your Blood: FDA Approves First Treatment for Warm Autoimmune Hemolytic Anemia

Investigational Therapy Shows Promise for Guillain-Barré Syndrome in Late-Stage Testing

As reported on Newsweek, a novel experimental treatment for Guillain-Barré syndrome (GBS) may represent a major advance for patients living with the rare neurological disorder. New findings released by biotechnology…

Continue Reading Investigational Therapy Shows Promise for Guillain-Barré Syndrome in Late-Stage Testing

When Your Cells’ Quality Control System Breaks Down: Understanding a Major Discovery in Rare Disease Research

The Basic Problem: Why One Bad Gene Can Cause Big Trouble Imagine your body as a giant factory. Like any factory, it needs quality control—machines that make sure good products…

Continue Reading When Your Cells’ Quality Control System Breaks Down: Understanding a Major Discovery in Rare Disease Research

FDA Approves Regeneron’s Pasatru for Fibrodysplasia Ossificans Progressiva, Expanding Treatment Options

As reported on BioSpace, the U.S. Food and Drug Administration has approved Regeneron’s Pasatru (garetosmab) for adults with fibrodysplasia ossificans progressiva (FOP), a rare genetic disorder that causes bone to…

Continue Reading FDA Approves Regeneron’s Pasatru for Fibrodysplasia Ossificans Progressiva, Expanding Treatment Options

Possible Mechanism Linking Amyloid and Tau Offers New Direction for Alzheimer’s Therapy

As reported on Scientific American, a growing body of research suggests that Alzheimer’s disease progression is driven by a complex interplay between beta-amyloid plaques and tau neurofibrillary tangles. While both…

Continue Reading Possible Mechanism Linking Amyloid and Tau Offers New Direction for Alzheimer’s Therapy

Diagnosing the Undiagnosed in Rare Disease: Worldwide, Multi-Institution, and Multi-disciplinary Work Underway

Recently at the World Orphan Drug Conference in Boston, Patient Worthy had the opportunity to meet with Dave Pearce PhD, Chair of International Rare Disease Research Consortium, (IRDiRC) Professor of…

Continue Reading Diagnosing the Undiagnosed in Rare Disease: Worldwide, Multi-Institution, and Multi-disciplinary Work Underway

TearSolutions Advances Lacripep® for Neurotrophic Keratitis with FDA Designations and Phase 2 Trial Launch

As reported on Business Wire, TearSolutions, a clinical-stage biotechnology company focused on ophthalmic therapies, has announced key regulatory and clinical progress for its investigational drug Lacripep® in the treatment of…

Continue Reading TearSolutions Advances Lacripep® for Neurotrophic Keratitis with FDA Designations and Phase 2 Trial Launch

RNA “Origami” Nanopore Technique Shows Promise for Faster Diagnosis of Repeat Expansion Disorders

As reported on MedicalXpress, a newly developed RNA-focused analytical method may improve the detection and characterization of repeat expansion disorders, a group of genetic conditions that includes Huntington’s disease, amyotrophic…

Continue Reading RNA “Origami” Nanopore Technique Shows Promise for Faster Diagnosis of Repeat Expansion Disorders

Awareness Isn’t the Hard Part — What 18 Years in the Moebius Syndrome Community Has Taught Me

For nearly two decades, I’ve been building and maintaining a global online community for individuals and families affected by Moebius syndrome, a rare neurological condition that most people have never…

Continue Reading Awareness Isn’t the Hard Part — What 18 Years in the Moebius Syndrome Community Has Taught Me